Cullinan Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cullinan Oncology LLC
CGEM Stock  USD 12.23  0.38  3.21%   
Cullinan Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cullinan Oncology's valuation are provided below:
Gross Profit
18.9 M
Market Capitalization
722.5 M
Enterprise Value Revenue
11.5457
Earnings Share
(3.32)
There are over one hundred nineteen available fundamental signals for Cullinan Oncology LLC, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Cullinan Oncology's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 63.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.86, Dividend Yield of 0.0 or PTB Ratio of 1.05. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
  
Build AI portfolio with Cullinan Stock
Check out the analysis of Cullinan Oncology Correlation against competitors.

Cullinan Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets750.9 M715.1 M232.6 M
Slightly volatile
Total Current Liabilities37 M35.2 M10.9 M
Slightly volatile
Other Liabilities55.6 K58.5 K246.8 K
Slightly volatile
Accounts Payable2 M1.9 M1.5 M
Slightly volatile
Other Current Assets15.3 M14.6 M4.4 M
Slightly volatile
Total Liabilities28.8 M36.2 M25.6 M
Slightly volatile
Common Stock7.5 K5.4 K9.6 K
Slightly volatile
Cash66.3 M95.5 M50.5 M
Slightly volatile
Long Term Debt282.5 K297.4 K564.7 K
Slightly volatile
Net Receivables1.9 M3.5 M2.7 M
Slightly volatile
Short and Long Term Debt152.2 K160.2 K477.2 K
Slightly volatile
Total Current Assets500.7 M476.9 M177.9 M
Slightly volatile
Short Term Debt1.2 M1.5 M1.3 M
Slightly volatile
Other Current Liabilities33.4 M31.8 M9.1 M
Slightly volatile
Property Plant And Equipment Net1.9 M2.7 M1.1 M
Slightly volatile
Non Current Assets Total250.1 M238.2 M54.9 M
Slightly volatile
Non Currrent Assets Other469.4 K329.4 K377 K
Pretty Stable
Cash And Short Term Investments309 M458.8 M176.8 M
Slightly volatile
Common Stock Total Equity6 K5.8 K2.5 K
Slightly volatile
Common Stock Shares Outstanding36.4 M61.8 M19.8 M
Slightly volatile
Liabilities And Stockholders Equity385.6 M715.1 M225.4 M
Slightly volatile
Non Current Liabilities Total725.9 K764.1 K37.2 M
Slightly volatile
Other Stockholder Equity1.2 B1.1 B314 M
Slightly volatile
Property Plant And Equipment Gross2.1 M3.5 M1.2 M
Slightly volatile
Capital Stock3.5 K6.9 K2.4 K
Slightly volatile
Net Working Capital298.8 M441.6 M170.9 M
Slightly volatile
Property Plant Equipment1.4 M1.4 M516.2 K
Slightly volatile
Deferred Long Term Liabilities55.6 K58.5 K1.4 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity322.4 K362.7 K395.9 K
Slightly volatile
Capital Surpluse643.5 M673.1 M593.5 M
Slightly volatile
Short and Long Term Debt Total2.9 M1.9 M4.6 M
Slightly volatile

Cullinan Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative63.8 M60.7 M19 M
Slightly volatile
Research Development172.6 M164.3 M51.5 M
Slightly volatile
Non Recurring97.2 K183.9 K119 K
Slightly volatile
Net Interest Income35.8 M34.1 M7.8 M
Slightly volatile
Interest Income35.8 M34.1 M7.8 M
Slightly volatile
Depreciation And Amortization369.5 K351.9 K117.8 K
Slightly volatile
Other Operating Expenses237.8 M226.5 M76.3 M
Slightly volatile
Reconciled Depreciation369.5 K351.9 K117.8 K
Slightly volatile
Non Operating Income Net Other3.9 M7.7 M2.2 M
Slightly volatile
Selling And Marketing Expenses764.4 K804.6 K34.8 M
Slightly volatile

Cullinan Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow97.7 M95.5 M72 M
Slightly volatile
Begin Period Cash Flow98.6 M113.2 M71.8 M
Slightly volatile
Depreciation369.5 K351.9 K117.8 K
Slightly volatile
Issuance Of Capital Stock317.2 M302 M85.2 M
Slightly volatile
Stock Based Compensation24.8 M43.5 M12 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio28.8632.4735.4412
Slightly volatile
Stock Based Compensation To Revenue1.031.161.2642
Slightly volatile
Capex To Depreciation0.570.64.7581
Slightly volatile
EV To Sales26.3429.6332.3416
Slightly volatile
Payables Turnover0.170.160.1439
Pretty Stable
Sales General And Administrative To Revenue1.231.381.5111
Slightly volatile
Research And Ddevelopement To Revenue2.442.742.9947
Slightly volatile
Capex To Revenue0.02490.0280.0306
Slightly volatile
Cash Per Share8.118.5331.4494
Slightly volatile
Days Payables Outstanding1.7 K1.8 K5.6 K
Very volatile
Net Debt To EBITDA0.530.561.8043
Slightly volatile
Current Ratio24.7215.5623.7833
Slightly volatile
Debt To Equity0.00780.00420.0088
Slightly volatile
Capex Per Share0.00550.00580.1774
Slightly volatile
Revenue Per Share0.340.380.4197
Slightly volatile
Interest Debt Per Share0.08860.0460.1032
Slightly volatile
Debt To Assets0.00740.0040.0084
Slightly volatile
Graham Number20.523.0625.1676
Slightly volatile
Days Of Payables Outstanding1.7 K1.8 K5.6 K
Very volatile
Ebt Per Ebit1.060.980.9722
Very volatile
Total Debt To Capitalization0.00770.00420.0087
Slightly volatile
Debt Equity Ratio0.00780.00420.0088
Slightly volatile
Quick Ratio24.7215.5623.7833
Slightly volatile
Net Income Per E B T0.720.90.9033
Slightly volatile
Cash Ratio2.963.1117.1234
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0271
Slightly volatile
Fixed Asset Turnover197221242
Slightly volatile
Debt Ratio0.00740.0040.0084
Slightly volatile
Price Sales Ratio28.8632.4735.4412
Slightly volatile
Asset Turnover0.03460.0390.0426
Slightly volatile

Cullinan Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap381.2 M428.8 M468.1 M
Slightly volatile
Enterprise Value260.4 M293 M319.8 M
Slightly volatile

Cullinan Fundamental Market Drivers

Forward Price Earnings6.3012
Cash And Short Term Investments399 M

Cullinan Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cullinan Oncology Financial Statements

Cullinan Oncology investors utilize fundamental indicators, such as revenue or net income, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue351.9 K369.5 K
Stock Based Compensation To Revenue 1.16  1.03 
Sales General And Administrative To Revenue 1.38  1.23 
Research And Ddevelopement To Revenue 2.74  2.44 
Capex To Revenue 0.03  0.02 
Revenue Per Share 0.38  0.34 
Ebit Per Revenue(3.23)(3.39)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
How To Invest In Cullinan
Details
Is Cullinan Stock a good investment?
Details
What is Cullinan Oncology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cullinan Oncology Correlation against competitors.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Biotechnology sector continue expanding? Could Cullinan diversify its offerings? Factors like these will boost the valuation of Cullinan Oncology. Projected growth potential of Cullinan fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cullinan Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.32)
Return On Assets
(0.27)
Return On Equity
(0.40)
Investors evaluate Cullinan Oncology LLC using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cullinan Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cullinan Oncology's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cullinan Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cullinan Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cullinan Oncology's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY